Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03473223 · ClinicalTrials.gov registry record · Phase 3
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
A Phase 3 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 3
- Development phase
- 18,226
- Enrollment target
NCT03473223 is a Phase 3 study that has completed, run by CSL Behring. The registered enrollment target is 18,226 participants.
The verdict
NCT03473223, a Phase 3 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 18,226 participants
- Enrollment target
Study Summary
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events \[MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke\] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.
Interventions
- OTHER Placebo
- BIOLOGICAL Apolipoprotein A-I [human] (apoA-I)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18,226 participants |
| Start Date | 2018-03-21 |
| Est. Completion | 2023-11-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03473223
The ClinicalTrials.gov registry entry for NCT03473223 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 18,226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03473223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03473223 about?
NCT03473223 is a clinical study titled "Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome". This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events \[MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke\] in subjects with acute coronar...
What is the current status of trial NCT03473223?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 18,226 participants. The study started on 2018-03-21. Estimated completion is 2023-11-17.
What interventions are being tested in trial NCT03473223?
The interventions under investigation include: Placebo (OTHER), Apolipoprotein A-I [human] (apoA-I) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03473223?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.